IDEAYA Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.03.25	IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery (RTTNews)
28.02.25	IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Rule 5635(c)(4) (RTTNews)
13.02.25	IDEAYA, Gilead To Evaluate Efficacy, Safety Of IDE397+Trodelvy Combination, Stock Up In Pre-Market (RTTNews)
13.02.25	IDEAYA Biosciences Q4 Loss Misses Estimates (RTTNews)
10.02.25	IDEAYA Appoints Joshua Bleharski As CFO (RTTNews)
30.12.24	IDEAYA Signs License Agreement For ADC SHR-4849 With Jiangsu Hengrui Pharma (RTTNews)
29.12.24	IDEAYA Enters License Deal With Hengrui Pharma To Develop SHR-4849 Worldwide Outside Of GreaterChina (RTTNews)
23.09.24	Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate (Benzinga)
23.09.24	IDEAYA Announces Positive Interim Phase 2 Data For Darovasertib In Neoadjuvant Uveal Melanoma (RTTNews)
10.07.24	IDEAYA Biosciences Announces Pricing Of Public Offering Of Common Stock And Pre-funded Warrants (RTTNews)
08.07.24	MÄRKTE USA/Kaum Bewegung - S&P-500 und Nasdaq mit neuen Rekordhochs (Dow Jones)
08.07.24	IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer (Benzinga)
08.07.24	MÄRKTE USA/Wenig verändert - S&P-500 und Nasdaq mit neuen Rekordhochs (Dow Jones)
08.07.24	MÄRKTE USA/Dow maschiert vorneweg - S&P-500 und Nasdaq mit Rekorden (Dow Jones)
08.07.24	MÄRKTE USA/Wall Street nach Rekordjagd kaum verändert gesehen (Dow Jones)
07.07.24	D-Day For IDEAYA - IDE397 Data To Be Unveiled Tomorrow (RTTNews)
08.05.24	Unveiling 5 Analyst Insights On IDEAYA Biosciences (Benzinga)
12.03.24	IDEAYA In Clinical Trial Deal With Merck To Evaluate IDE161 With KEYTRUDA In Endometrial Cancer (RTTNews)
08.03.24	Demystifying IDEAYA Biosciences: Insights From 6 Analyst Reviews (Benzinga)
20.02.24	IDEAYA Biosciences Q4 Results Misses Estimates (RTTNews)
05.02.24	Biotech High-Flyers That Just Hit 52-Week Highs (RTTNews)
29.12.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
08.12.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
05.12.23	IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event (PR Newswire)
04.12.23	IDEAYA To Evaluate IDE397 In Combination With Gilead's Trodelvy - Quick Facts (RTTNews)
04.12.23	IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
03.12.23	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 (PR Newswire)
07.11.23	IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
01.11.23	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference (PR Newswire)
27.10.23	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
27.10.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
25.10.23	IDEAYA Biosciences Prices Public Offering Of 5 Mln Shares Of Common Stock At $23.50/shr (RTTNews)
25.10.23	IDEAYA Announces Pricing of Public Offering (PR Newswire)
24.10.23	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
23.10.23	IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Leth... (PR Newswire)
17.10.23	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma (PR Newswire)
16.10.23	IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma (PR Newswire)
09.10.23	IDEAYA Biosciences Selects Werner Helicase Inhibitor Development Candidate With GSK (RTTNews)
09.10.23	IDEAYA Biosciences Announces Development Candidate Nomination of a Werner Helicase Inhibitor in Collaboration with GSK and Investor R&D Day (PR Newswire)
06.10.23	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
27.09.23	IDEAYA Biosciences: IDE161 Granted Fast Track Status By FDA (RTTNews)
27.09.23	IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	89.68	1.22 %	K V
Novartis	99.23	0.31 %	K V
Swisscom	515.00	0.29 %	K V
Roche Hldg G	303.40	0.26 %	K V
Lonza Grp	576.20	-0.24 %	K V
Part Grp Hldg	1’328.00	-3.73 %	K V
Sika	222.60	-3.97 %	K V
UBS Group	29.66	-5.09 %	K V
Logitech Intl	84.88	-5.12 %	K V
Kuehne+Nagel Int	201.70	-6.01 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu IDEAYA Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten